Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 05, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

July 25, 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

Dapagliflozin Boosts Health Status Across LVEF Range

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

May 23, 2022

Good News and Bad for High-Intensity Statin Use in ASCVD

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

January 10, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.